Evidence map›Paper›PMID 38542143›Full record

ReviewInternational journal of molecular sciences2024

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.

Morgan Bailey, Susan Morand, Rachel Royfman, Leslie Lin, Aditi Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John Nemunaitis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Morgan BaileyDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.
Susan MorandDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.ORCID 0000-0001-9594-0094
Rachel RoyfmanDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.
Leslie LinDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.
Aditi SinghDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.
Laura StanberyGradalis, Inc., Dallas, TX 75006, USA.
Adam WalterGradalis, Inc., Dallas, TX 75006, USA.
Danae HamoudaDepartment of Medicine, University of Toledo, Toledo, OH 43614, USA.ORCID 0000-0003-0064-2460
John NemunaitisGradalis, Inc., Dallas, TX 75006, USA.ORCID 0000-0002-2234-2381
University of Toledo · USGradalis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi's), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi's have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in

Indexed as

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBiomarkersFemaleHomologous RecombinationHumansImmune Checkpoint InhibitorsBiomarkersImmune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase InhibitorsBRCAcheckpoint inhibitorhomologous recombinationHRDHRPimmunotherapyovarian cancerPARP inhibitor

Identifiers

PMID38542143
PMCPMC10970335
OpenAlexW4392654441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.